Calculators and Tools for Diabetes Management

ADA 2026 guidelines recommend an HbA1c target <7% (53 mmol/mol) for most non-pregnant adults with type 2 diabetes. A target of <8% is appropriate for older adults, those with limited life expectancy, advanced complications, or high hypoglycemia risk. More stringent targets (<6.5%) may be individualized in younger patients with recent diagnosis and low hypoglycemia risk. HbA1c should be checked every 3 months when not at target, and every 6 months once stable.

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) estimates insulin resistance from fasting insulin and fasting glucose: HOMA-IR = fasting insulin (µIU/mL) × fasting glucose (mmol/L) ÷ 22.5. Values >2.0–2.5 suggest insulin resistance; >3.0 is a common clinical cut-off. Both measurements must be taken fasting (8–12 hours). HOMA-IR is a useful marker of metabolic syndrome and a predictor of type 2 diabetes risk, but it is a research tool rather than a standard diagnostic test.

Diabetic nephropathy is the leading cause of chronic kidney disease worldwide. eGFR <60 mL/min/1.73m² (Stage 3 CKD) combined with albuminuria (urine ACR >30 mg/g) defines diabetic kidney disease. Key medication thresholds: metformin — reduce dose at eGFR 30–45, stop at <30; SGLT2 inhibitors — still beneficial for kidney/heart protection down to eGFR 20 (empagliflozin, dapagliflozin); GLP-1 agonists — most can be used down to eGFR 15. Monitor eGFR and urine ACR at least annually in all people with diabetes.

The ACC/AHA Pooled Cohort Equations (ASCVD risk) estimate 10-year cardiovascular risk. In diabetes, statin therapy is recommended for all adults aged 40–75 — high-intensity statins for those with ≥7.5% ASCVD risk or additional risk factors (LDL ≥190, established ASCVD). SGLT2 inhibitors (empagliflozin, dapagliflozin) and GLP-1 agonists (semaglutide, liraglutide) have proven cardiovascular mortality benefits in high-risk T2DM and should be prioritized over glucose-lowering efficacy alone.

The insulin correction factor (sensitivity factor) estimates how much 1 unit of rapid-acting insulin lowers blood glucose. Use the '1800 rule': Correction Factor = 1800 ÷ Total Daily Dose (TDD). Example: TDD = 50 units → correction factor = 36 mg/dL per unit. Correction dose = (current blood glucose − target blood glucose) ÷ correction factor. This should be verified against the patient's actual glucose response and individualized — the 1800 rule is a starting estimate, not a fixed formula.

ADA 2026 recommends a blood pressure target <130/80 mmHg for most adults with diabetes and hypertension, if achievable without undue treatment burden. A target <140/90 mmHg is acceptable for lower-risk patients. First-line agents for people with diabetes: ACE inhibitors or ARBs (especially with albuminuria — they provide kidney-protective benefits beyond BP lowering). Thiazide diuretics and CCBs are appropriate add-on agents. Avoid combining ACE inhibitors with ARBs due to increased adverse effects without additional benefit.